Munich-based biotech company Genomatix AG sold to market-leading listed corporation

Munich, 29th October 2018. Attorney Rolf G. Pohlmann was able to sell Genomatix AG to a listed market leader within the biotech industry from outside Europe in the course of a transferred restructuring.

Headquartered in Munich, Genomatix AG is a spin-off from the Munich Helmholtz Institute and one of the world’s leading suppliers of technologies to analyze and interpret genomic data. As well as laying the groundwork for microarray experiments and NGS data sequencing analyses, the hardware and software solutions also help to answer the typical questions posed by systems biology.

Across the last two decades, Genomatix has developed industry-leading software tools focused on mapping genomic, transcriptomic, and epigenomic functions in eukaryotic microbes and multicellular organisms employing diverse experimental inputs (microarray, ChipSeq, and Next-Gen Sequencing (NGS)). Over 30,000 customers, including private and public companies as well as institutional organizations within the pharma industry, use the company’s unique data base and solutions.

Attorney Rolf G. Pohlmann from the law firm Pohlmann Hofmann Insolvency Administration in Munich has been announced as preliminary insolvency administrator and was confirmed with the opening of the insolvency proceedings on October 1st, 2018. By continuing with the daily business of Genomatix and securing all ongoing studies and projects without limitations, the insolvency administrators were able to run an international M&A process. “The successful closing of the transaction is not only essential to the firm’s survival, its values and many years of research, but also to all non-subordinated creditors that have been satisfied with a rate of up to 100% and of course to the employees in Germany, whose workplaces could be saved,” said Pohlmann.

ACXIT Recovery Management, together with ACXIT Capital Partners’ biotech experts, has been mandated by the insolvency administrator as the exclusive M&A advisor.

About Pohlmann Hofmann Insolvency Administrator

Pohlmann Hofmann is a German law firm specialized in insolvency administration and serving as the supervisor (debtor-in-possession-cases), especially for reorganization of companies. In Germany, Pohlmann Hofmann is counted among the leading insolvency administration law offices. With its four insolvency administrators, 20 lawyers and economists in a team of in total more than 50 staff members, and with offices based in Munich, Augsburg and Ulm, the law office is able to handle insolvency and reorganization cases of almost any size anywhere in Germany. (http://pohlmannhofmann.de/)

About ACXIT Recovery Management

ACXIT Recovery Management, a part of ACXIT Capital Partners, is an independent consultancy firm exclusively dedicated to distressed mergers & acquisitions. ACXIT Recovery delivers tailored solutions and transactions for small and medium sized companies as well as for insolvency administrators. The managing partners of ACXIT Recovery have been in charge of more than 100 successful transactions in restructuring and insolvency situations over the last eight years.

ACXIT Capital Partners is a leading international corporate finance and investment advisory firm for mid-market clients and entrepreneurs in Europe and abroad. As an independent and privately owned firm, ACXIT maintains offices in Frankfurt, Berlin, Munich, Leipzig, Zurich, and Hong Kong as well as strong alliances in France, China, India, and the USA.

PRESS CONTACT

ACXIT Capital Holding GmbH
WestendDuo
Bockenheimer Landstraße 24
60323 Frankfurt am Main
Germany
www.acxit.com

facebook.com/acxitcapital
twitter.com/acxitcapital
xing.com/companies/acxitcapitalpartners
linkedin.com/company/acxit-capital-partners

Dr. Hartmut Vennen
Senior Managing Director, Strategic Communications

FTI Consulting
Park Tower | Bockenheimer Anlage 44
60322 Frankfurt am Main
Phone: +49 69 92037 137
Mobile: +49 160 895 5858
E-mail: hartmut.vennen@fticonsulting.com

TRANSACTION TEAM

Nikolaus J. Röver, Managing Partner
Klaus Nestler, Managing Director, Head of Lifescience